Dutasteride is employed either as a standalone treatment or in conjunction with another medication (tamsulosin [Flomax]) to address benign prostatic hyperplasia (BPH), the enlargement of the prostate gland. Dutasteride effectively alleviates BPH symptoms and mitigates the risk of sudden urinary retention. Additionally, it can reduce the likelihood of requiring prostate surgery. This medication falls under the category of 5-alpha reductase inhibitors, functioning by impeding the production of a naturally occurring substance responsible for prostate enlargement.

Biktarvy stands as a testament to medical innovation, skillfully blending the unique attributes of Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide into a consolidated therapeutic powerhouse. Central to this fusion is Bictegravir Sodium, a potent integrase strand transfer inhibitor, which plays a pivotal role in obstructing the virus’s ability to integrate its genetic material into human cells.